Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin augmentation of dipyridamole-induced vasodilation via adenosine receptor stimulation
2007-004762-40Phase 4Active
- Sponsor
- Department of Pharmacology and Toxicology
- Start
- Aug 2007
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of rosuvastatin in ischemia-reperfusion injury (IRI) and peripheral arterial disease (PAD), sponsored by Department of Pharmacology and Toxicology. Primary endpoint: Forearm vasodilatory response to dipyridamole with and without caffeine. Started Aug 2007; status: active.
02
Drugs
rosuvastatin
03
Conditions
ischemia-reperfusion injury (IRI)peripheral arterial disease (PAD)
Beyond the preview
Go deeper on 2007-004762-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004762-40.